Rhinophototherapy in persistent allergic rhinitis Bella, Zsolt; Kiricsi, Ágnes; Viharosné, Éva Dósa-Rácz ...
European archives of oto-rhino-laryngology,
03/2017, Volume:
274, Issue:
3
Journal Article
Peer reviewed
Previous published results have revealed that Rhinolight
®
intranasal phototherapy is safe and effective in intermittent allergic rhinitis. The present objective was to assess whether phototherapy is ...also safe and effective in persistent allergic rhinitis. Thirty-four patients with persistent allergic rhinitis were randomized into two groups; twenty-five subjects completed the study. The Rhinolight
®
group was treated with a combination of UV-B, UV-A, and high-intensity visible light, while the placebo group received low-intensity visible white light intranasal phototherapy on a total of 13 occasions in 6 weeks. The assessment was based on the diary of symptoms, nasal inspiratory peak flow, quantitative smell threshold, mucociliary transport function, and ICAM-1 expression of the epithelial cells. All nasal symptom scores and nasal inspiratory peak flow measurements improved significantly in the Rhinolight
®
group relative to the placebo group and this finding persisted after 4 weeks of follow-up. The smell and mucociliary functions did not change significantly in either group. The number of ICAM-1 positive cells decreased non-significantly in the Rhinolight
®
group. No severe side-effects were reported during the treatment period. These results suggest that Rhinolight
®
treatment is safe and effective in persistent allergic rhinitis.
Background
The therapeutic effect of ultraviolet (UV) light is generally attributed to its immunosuppressive and immunomodulatory effects. Since chronic inflammation is the major factor in the ...development of nasal polyposis, we have previously used mixed ultraviolet-visible light (mUV-VIS, Rhinolight®) phototherapy for the treatment of nasal polyps.
Aims
In the present open, multicenter study, our aim was to delineate whether mUV-VIS applied
postoperatively
in vivo together with intranasal steroid treatment could reduce the recurrence of nasal polyps.
Methods
After functional endoscopic sinus surgery, one group of patients received mUV-VIS light together with standard intranasal steroid (mometason furoate 2 × 200 μg) application for a 12-week treatment period, whereas the other patient group obtained only intranasal steroid for the same duration. We recorded nasal endoscopy images and obtained demographical and clinical data, total nasal score (TNS), and nasal obstruction symptom evaluation (NOSE). We performed acoustic rhinometry and measured nasal inspiratory peak flow. Follow-up was 12 months.
Results
We found that the recurrence of nasal polyps was significantly diminished, and based on video-endoscopic measurements, the size and grade of recurrent polyps were significantly smaller in the phototherapy-receiving group. Nasal obstruction values and NOSE were significantly better throughout the follow-up period in the mUV-VIS light-treated group than in the intranasal steroid monotreatment group.
Conclusions
Rhinophototherapy together with standard nasal steroid application may have a supportive role in the treatment of recurrent bilateral nasal polyps.
Gyurus EK, Patterson C, Soltesz G and the Hungarian Childhood Diabetes Epidemiology Group. Twenty‐one years of prospective incidence of childhood type 1 diabetes in Hungary – the rising trend ...continues (or peaks and highlands?).
The aim of this study was to examine secular trends in the incidence of type 1 diabetes in children aged 0–14 yr in Hungary over the period 1989–2009. Newly diagnosed children with type 1 diabetes aged 0–14 yr in Hungary were prospectively registered from 1989 to 2009. Primary ascertainment of cases was by prospective registration using hospital notifications. Case ascertainment was over 96% complete using the capture–recapture method. Standardized incidence rates were calculated and secular trends estimated using Poisson regression analysis. In Hungary during 1989–2009 a total number of 3432 children were identified, giving a standardized incidence rate of 12.5 95% confidence interval (CI) 12.1–12.9 per 100 000 person yr. The overall incidence rate has doubled from 7.7 (95% CI 6.4–9.15) per 100 000 per yr in 1989 to 18.2 (95% CI 15.7–20.9) per 100 000 per yr in 2009. A significant linear trend in incidence (p < 0.001) has been observed over time, with a mean annual increase of 4.4%. The increase in incidence was present in both genders and in all age groups, with the largest relative increase in the youngest age group (6.2%; p < 0.001). The incidence of type 1 diabetes in Hungarian children continues to increase, with the highest rate in the very young. Although it seems that transient periods of stabilization followed by increases in incidence are apparent, the long‐term trend continues to be steadily upward. Incidence of childhood type 1 diabetes is a dynamic process, probably reflecting the changes of the environmental exposures and continued registration is necessary to recognize these trends.
Institute of Clinical Microbiology, Medical Faculty, University of Szeged, Szeged, Hungary
Corresponding author: Professor E. Nagy (e-mail: nagye{at}mlab.szote.u-szeged.hu ).
Received 28 Sept. 2001; ...revised version accepted 14 Feb. 2002.
Abstract
The purpose of this study was to evaluate the aetiology and susceptibility of different Candida species originating from blood cultures received from different clinical wards of the University Hospital in Szeged, Hungary, from 1996 to 2000. A total of 145 episodes of fungaemia occurred in 68 patients. In 73.5% of the patients the infections were due to Candida albicans , 7.3% to C. parapsilosis , 5.9% to C. krusei , 4.4% to C. tropicalis and 3% each to C. glabrata , other Candida spp. and Cryptococcus neoformans . There were no appreciable differences in the distribution of yeast species during the 5-year period: C. albicans remained the predominant species causing bloodstream infections in this hospital, similar to the results of other studies (Norway, SENTRY Program in USA, Canada and South America). Most of the Candida isolates (39.3%) were from blood cultures of patients hospitalised in surgical wards, 28.3% were from adult intensive care units (ICUs), 13.8% from paediatric ICUs, 11% from haematology and 7.6% from cardiology departments. MICs for amphotericin B, fluconazole and itraconazole were determined for 83% of the isolates. All isolates were susceptible to amphotericin B. The percentage of yeast isolates with decreased susceptibility or resistance to fluconazole was smaller (15.7%) than that for itraconazole (24%).
PDF